<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03469960</url>
  </required_header>
  <id_info>
    <org_study_id>IFCT-1701</org_study_id>
    <secondary_id>2017-002540-33</secondary_id>
    <nct_id>NCT03469960</nct_id>
  </id_info>
  <brief_title>Double Immune Checkpoint Inhibitors in PD-L1-positive Stage IV Non-small Lung CancEr</brief_title>
  <acronym>DICIPLE</acronym>
  <official_title>A Randomized Phase 3 Trial Comparing Continuation Nivolumab-Ipilimumab Doublet Immunotherapy Until Progression Versus Observation in Treatment-naive Patients With PDL1-positive Stage IV Non-Small Cell Lung Cancer (NSCLC) After Nivolumab-Ipilimumab Induction Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Intergroupe Francophone de Cancerologie Thoracique</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Intergroupe Francophone de Cancerologie Thoracique</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Non Small Cell lung cancer (NSCLC) remains the first cause of death by cancer in the World.&#xD;
      For the patients presenting a NSCLC stage IV, the median of survival is about 15 months&#xD;
      today. The chemotherapy with platinum is the standard treatment for these patients but&#xD;
      immunotherapy showed these efficacy in 1st line for patients PD-L1 positive. On the other&#xD;
      hand, the duration of treatment by immunotherapy is not clear. Indeed, prolonged responses&#xD;
      and long survivals have been described in patients having interrupted the treatment. In the&#xD;
      melanoma, a treatment of 6 months of ipilimumab demonstrated its efficacy. The objective of&#xD;
      the study is to demonstrate that a treatment of 6 months followed by an observation (stop and&#xD;
      go) is not less effective than a treatment given until progression or toxicity. This strategy&#xD;
      would allow to decrease the accumulated toxicities, to improve the quality of life of the&#xD;
      patients and to decrease the costs.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 2, 2018</start_date>
  <completion_date type="Anticipated">May 2023</completion_date>
  <primary_completion_date type="Anticipated">May 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS1)</measure>
    <time_frame>24 months after randomization of the last subject</time_frame>
    <description>Time between the date of randomization and the first date of documented progression, as determined by BICR (Blinded Independent Central Review), or death due to any cause, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival (PFS2)</measure>
    <time_frame>24 months after randomization of the last subject</time_frame>
    <description>Time between the start date of the second line and the second date of documented progression, as determined by BICR, or death due to any cause, whichever occurs first.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life (QoL)</measure>
    <time_frame>24 months after randomization of the last subject</time_frame>
    <description>Time until definitive deterioration (TUDD) from the randomization time in the experimental arm B.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>6, 12 and 18 months after randomization</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological correlative exploratory studies (PD-L1)</measure>
    <time_frame>6 months</time_frame>
    <description>PD-L1-stained % of tumor cells will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological correlative exploratory studies (PD-L1 H score)</measure>
    <time_frame>6 months</time_frame>
    <description>PD-L1 H-score will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological correlative exploratory studies (CD3/CD8)</measure>
    <time_frame>6 months</time_frame>
    <description>CD3/CD8 tumor infiltration will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological correlative exploratory studies (neutrophil)</measure>
    <time_frame>6 months</time_frame>
    <description>neutrophil tumor infiltration will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological correlative exploratory studies (cytokines)</measure>
    <time_frame>6 months</time_frame>
    <description>plasma concentration of different cytokines at baseline or at the randomization point, will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biological correlative exploratory studies (chemokines)</measure>
    <time_frame>6 months</time_frame>
    <description>plasma concentration of different chemokines at baseline or at the randomization point, will be associated to the rate of disease control patients at 6 months, PFS1, PFS2 and OS</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">1360</enrollment>
  <condition>Non-Small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Arm A : standard treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>6 months of treatment by nivolumab + ipilimumab then nivolumab + ipilimumab then in case of progression platinum-based doublet recommended</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Arm B : experimental arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 months of treatment by nivolumab + ipilimumab then observation the in case of progression nivolumab + ipilimumab then in case of progression platinum-based doublet recommended</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ipilimumab</intervention_name>
    <description>Ipilimumab 1 mg/kg every 6 weeks</description>
    <arm_group_label>Arm A : standard treatment</arm_group_label>
    <arm_group_label>Arm B : experimental arm</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Nivolumab 3 mg/kg every 2 weeks</description>
    <arm_group_label>Arm A : standard treatment</arm_group_label>
    <arm_group_label>Arm B : experimental arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed Written Informed Consent:&#xD;
&#xD;
             Subjects must have signed and dated an IRB/IEC approved written informed consent form&#xD;
             in accordance with regulatory and institutional guidelines. This must be obtained&#xD;
             before the performance of any protocol related procedures that are not part of normal&#xD;
             subject care.&#xD;
&#xD;
             Subjects must be willing and able to comply with scheduled visits, treatment schedule,&#xD;
             and laboratory testing.&#xD;
&#xD;
          2. Histologically-proven NSCLC (squamous or non-squamous)&#xD;
&#xD;
          3. Stage IV (M1, including M1a pleural involvement) disease (8th classification TNM, UICC&#xD;
             2015)&#xD;
&#xD;
          4. ECOG PS &lt; 1&#xD;
&#xD;
          5. Weight loss&lt; 10% in previous 3 months&#xD;
&#xD;
          6. No prior systemic anticancer therapy (including EGFR or ALK inhibitors) given as&#xD;
             primary therapy for advanced or metastatic disease.&#xD;
&#xD;
          7. Age≥ 18 years, &lt;75 years&#xD;
&#xD;
          8. Life expectancy &gt; 3 months&#xD;
&#xD;
          9. Measurable tumor disease by CT or MRI per RECIST 1.1 criteria&#xD;
&#xD;
         10. Available tumor samples for centralized PD-L1 immunohistochemistry analysis&#xD;
&#xD;
         11. PD-L1 tumor content ≥ 1% and &lt; 50% tumor cells as assessed locally by the investigator&#xD;
             center&#xD;
&#xD;
         12. Adequate biological functions:&#xD;
&#xD;
             Creatinine Clearance ≥ 50 mL/min (Cockcroft or MDRD or CKD-epi); neutrophiles ≥&#xD;
             1500/mm3 ; platelets ≥100 000/mm3 ; Hemoglobin ≥ 9g/dL ; hepatic enzymes &lt; 3x ULN,&#xD;
             total bilirubin ≤ 1,5 x ULN except for patients with proved, Gilbert syndrome (≤ 5 x&#xD;
             ULN) or patients with hepatic metastases (≤ 3,0 mg/dL)&#xD;
&#xD;
         13. Women of childbearing potential (WOCBP) and sexually active should use an efficacious&#xD;
             contraception method within the 28 days preceding the first dose and during the 6&#xD;
             months following the last dose of treatment. Women must have a negative serum or urine&#xD;
             pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24&#xD;
             hours prior to the start of study drug.&#xD;
&#xD;
             For Male subjects who are sexually active with WOCBP, an efficacious contraception&#xD;
             method should be used during the treatment and during the 7 months following the last&#xD;
             dose.&#xD;
&#xD;
             Investigators shall counsel WOCBP and male subjects who are sexually active with WOCBP&#xD;
             on the importance of pregnancy prevention and the implications of an unexpected&#xD;
             pregnancy. Investigators shall advise WOCBP and male subjects who are sexually active&#xD;
             with WOCBP on the use of highly effective methods of contraception. Highly effective&#xD;
             methods of contraception have a failure rate of &lt; 1% when used consistently and&#xD;
             correctly. At a minimum, subjects must agree to the use of two methods of&#xD;
             contraception, with one method being highly effective and the other method being&#xD;
             either highly effective or less effective.&#xD;
&#xD;
         14. Patient inclusion validated by a multidisciplinary meeting.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Small cell lung cancer or tumors with mixt histology including a SCLC component&#xD;
&#xD;
          2. Known EGFR activating tumor mutation (deletion LREA in exon 19, L858R ou L861X&#xD;
             mutations in exon 21, G719A/S mutation in exon 18) or HER exon 20 insertion (either&#xD;
             tissue or plasma cfDNA mutation).&#xD;
&#xD;
          3. Known ALK or ROS1 gene rearrangement as assessed by immunohistochemistry, FISH or NGS&#xD;
             sequencing&#xD;
&#xD;
          4. Previous or active cancer within the previous 5 years (except for treated carcinoma in&#xD;
             situ of the cervix or basal cell skin cancer). Patients with a prostate adenocarcinoma&#xD;
             history within the previous 5 years could be included in case of localized prostate&#xD;
             cancer, with good prognostic factors according to d'Amico classification (≤ T2a and&#xD;
             Score de Gleason ≤ 6 and PSA (ng/ml) ≤ 10), provided they were treated in a curative&#xD;
             way (surgery or radiotherapy, without any chemotherapy)&#xD;
&#xD;
          5. Superior vena cava (SVC) syndrome persisting after SVC stenting&#xD;
&#xD;
          6. Thoracic radiotherapy needed at initiation of tumor treatment, except bone palliative&#xD;
             radiotherapy on a painful or compressive metastasis, respecting 4 weeks delay between&#xD;
             the end of radiotherapy and the beginning of induction immunotherapy treatment&#xD;
&#xD;
          7. Symptomatic untreated brain metastasis (without previous whole brain radiotherapy or&#xD;
             stereotactic ablative brain radiotherapy or without surgical resection). At least 4&#xD;
             weeks delay between the end of radiotherapy and the beginning of induction&#xD;
             immunotherapy treatment should be respected. Asymptomatic brain metastasis, not&#xD;
             needing corticosteroids greater than 10 mg prednisone equivalent daily or mannitol&#xD;
             infusions, with no evolution on brain MRI or CT-scan within the previous month are&#xD;
             allowed.&#xD;
&#xD;
          8. History of previous primary immunodeficiency, organ transplantation needing an&#xD;
             immunosuppressive treatment, any immunosuppressive drug within 28 days before&#xD;
             randomization date, or history of severe toxicity (grade 3/4) by immune mechanism&#xD;
             linked to another immunotherapy treatment.&#xD;
&#xD;
          9. Systemic treatment with corticosteroids with greater dose than 10 mg prednisone&#xD;
             equivalent daily, within 14 days before initiation of the immunotherapy induction.&#xD;
             Inhaled, nasal or topic corticosteroids are allowed.&#xD;
&#xD;
         10. History of active autoimmune disease including rheumatoid polyarthritis, Lupus,&#xD;
             Wegener disease. Patients with type I diabetes, or hypothyroidism, or immune cutaneous&#xD;
             disease (vitiligo, psoriasis, alopecia) not needing any immunosuppressive systemic&#xD;
             treatment, are allowed to be included.&#xD;
&#xD;
         11. Active inflammatory intestinal disease (diverticulosis, Crohn disease, Hemorrhagic&#xD;
             recto-colitis, coeliac disease) or any serious chronic intestinal disease with&#xD;
             uncontrolled diarrhea&#xD;
&#xD;
         12. Active uncontrolled infection including tuberculosis, known acute viral hepatitis B&#xD;
             and C according to serological tests. Patients with serological sequelae of cured&#xD;
             viral hepatitis are allowed to be included.&#xD;
&#xD;
         13. HIV known infection&#xD;
&#xD;
         14. Living attenuated vaccine received within the 30 previous days&#xD;
&#xD;
         15. Previous treatment with anti-PD-1, anti-PD-L1 or Anti-CTLA4 antibody&#xD;
&#xD;
         16. Previous treatment with chemotherapy&#xD;
&#xD;
         17. General serious condition such as congestive uncontrolled cardiac failure,&#xD;
             uncontrolled cardiac arrythmia, uncontrolled ischemic cardiac disease (unstable angina&#xD;
             or history of myocardial infarction in the previous 6 months), history or stroke&#xD;
             within the 6 previous months&#xD;
&#xD;
         18. Pre-existing lung interstitial disease as assessed by the diagnosis CT-scan.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Clinical Operations Manager</last_name>
    <phone>0156811046</phone>
    <phone_ext>33</phone_ext>
    <email>contact@ifct.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Amiens - CHU</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Claire POULET, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Angers - CHU</name>
      <address>
        <city>Angers</city>
        <zip>49000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thierrry Urban, Pr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Annecy - CH</name>
      <address>
        <city>Annecy</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dorine TEMPLEMENT, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Argenteuil -CH</name>
      <address>
        <city>Argenteuil</city>
        <zip>95100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure BELMONT, Dr</last_name>
    </contact>
    <contact_backup>
      <email>contact@ifct.fr</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>Avignon - CH</name>
      <address>
        <city>Avignon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicolas Cloarec, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bordeaux - Polyclinique Nord</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sigolène GALLAND-GIRODET, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
    <investigator>
      <last_name>Sigolène GALLAND GIRODET, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Boulogne - Ambroise Paré</name>
      <address>
        <city>Boulogne-Billancourt</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Etienne GIROUX-LEPRIEUR, MD</last_name>
    </contact>
    <investigator>
      <last_name>Etienne GIROUX-LEPRIEUR, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Caen - CHU Côte de Nacre</name>
      <address>
        <city>Caen</city>
        <zip>14000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeannick MADELAINE, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Cahors - CH</name>
      <address>
        <city>Cahors</city>
        <zip>46000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patricia Barré, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Pontoise</name>
      <address>
        <city>Cergy Pontoise</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile DURAND, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Chambery</name>
      <address>
        <city>Chambery</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne BARANZELLI, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Chauny</name>
      <address>
        <city>Chauny</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Patrick DUMONT</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH</name>
      <address>
        <city>Cholet</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Philippe MASSON</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clamart - Hôpital Percy</name>
      <address>
        <city>Clamart</city>
        <zip>92140</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier BYLICKI, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clermont Ferrand - CHU</name>
      <address>
        <city>Clermont Ferrand</city>
        <zip>63000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lise THIBONNIER, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colmar - CH</name>
      <address>
        <city>Colmar</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Lionel MOREAU, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dijon - CAC</name>
      <address>
        <city>Dijon</city>
        <zip>21000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Laure Favier, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU Grenoble</name>
      <address>
        <city>Grenoble</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Anne-Claire TOFFART</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>La Roche Sur Yon - CH</name>
      <address>
        <city>La Roche Sur Yon</city>
        <zip>85925</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie MARCQ, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier - Pneumologie</name>
      <address>
        <city>Le Mans</city>
        <zip>72000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Olivier Molinier, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alexis CORTOT, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU de Limoges</name>
      <address>
        <city>Limoges</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Thomas EGENOD, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH Lyon Sud - Pneumologie</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sébastien COURAUD</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institut Paoli Calmette</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anne MADROSZYK, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Marseille - Hôpital Européen</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques LE TREUT, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mont de Marsan - CH</name>
      <address>
        <city>Mont de Marsan</city>
        <zip>40000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jérome Dauba, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Mulhouse - CH</name>
      <address>
        <city>Mulhouse</city>
        <zip>68000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Didier DEBIEUVRE, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nantes - Centre René Gauducheau</name>
      <address>
        <city>Nantes</city>
        <zip>44805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sandrine HIRET, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Antoine Lacassagne</name>
      <address>
        <city>Nice</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Josiane OTTO, MD</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvie VAN HULST, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Orléans - CH</name>
      <address>
        <city>Orléans</city>
        <zip>45000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Adrien DIXMIER, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>AP-HP Hopital Tenon - Pneumologie</name>
      <address>
        <city>Paris</city>
        <zip>75020</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jacques Cadranel, Pr</last_name>
      <phone>+33.1.56.01.65.31</phone>
      <email>contact@ifct.fr</email>
    </contact>
    <investigator>
      <last_name>Jacques Cadranel, pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>AP-HP Hôpital Bichat</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gérard Zalcman, PhD</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>GH Paris Saint-Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jean-Pierre TREDANIEL</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hôpital Saint Louis APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ludovic DOUCET, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Paris - Institut Curie</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sophie BEAUCAIRE-DANEL, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Rouen - CHU</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc Thiberville, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saint Quentin - CH</name>
      <address>
        <city>Saint Quentin</city>
        <zip>02100</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Charles Dayen, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre René Huguenin</name>
      <address>
        <city>Saint-Cloud</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Marie-Ange Massiani, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>HIA Begin</name>
      <address>
        <city>Saint-Mandé</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carole HELISSEY, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICL Lucien Neuwirth</name>
      <address>
        <city>Saint-Priest-en-Jarez</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Pierre FOURNEL, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Suresnes - Hopital Foch</name>
      <address>
        <city>Suresnes</city>
        <zip>92151</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sylvie Friard, Dr</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Toulon - CHI</name>
      <address>
        <city>Toulon</city>
        <zip>83000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Clarisse Audigier-Valette, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHU Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julien MAZIERES, Pr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CHRU de Tours</name>
      <address>
        <city>Tours</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eric PICHON, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Versailles - CH</name>
      <address>
        <city>Versailles</city>
        <zip>78157</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cécile DUJON, Dr</last_name>
      <email>contact@ifct.fr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CH de Villefranche - Pneumologie</name>
      <address>
        <city>Villefranche</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luc ODIER</last_name>
      <email>contact@ifct.fr</email>
    </contact>
    <investigator>
      <last_name>Luc ODIER</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>https://www.ifct.fr/index.php/fr/la-recherche/item/2105-ifct-1701-diciple</url>
    <description>IFCT website</description>
  </link>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>February 16, 2018</study_first_submitted>
  <study_first_submitted_qc>March 12, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 19, 2018</study_first_posted>
  <last_update_submitted>October 8, 2020</last_update_submitted>
  <last_update_submitted_qc>October 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>IFCT</keyword>
  <keyword>DICIPLE</keyword>
  <keyword>NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Ipilimumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

